{'52WeekChange': 0.87659574,
 'SandP52WeekChange': None,
 'address1': '830 Winter Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.24,
 'askSize': 1000,
 'averageDailyVolume10Day': 2368800,
 'averageVolume': 2415339,
 'averageVolume10days': 2368800,
 'beta': 2.466106,
 'beta3Year': None,
 'bid': 4.23,
 'bidSize': 3100,
 'bookValue': -0.024,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.38,
 'dayLow': 4.185,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -10.482,
 'enterpriseToRevenue': 5.94,
 'enterpriseValue': 516587104,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.556,
 'fiftyTwoWeekHigh': 7.07,
 'fiftyTwoWeekLow': 1.95,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 145363859,
 'forwardEps': -0.76,
 'forwardPE': -5.5657897,
 'fromCurrency': None,
 'fullTimeEmployees': 75,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01115,
 'heldPercentInstitutions': 0.76608,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/immunogen.com',
 'longBusinessSummary': 'ImmunoGen, Inc., a clinical-stage biotechnology '
                        'company, develops antibody-drug conjugate (ADC) '
                        'therapies to treat cancer. Its product candidates '
                        'include mirvetuximab soravtansine, an ADC targeting '
                        'folate-receptor alpha, which is in Phase III clinical '
                        'trial for the treatment of platinum-resistant ovarian '
                        'cancer; IMGN779 that is in Phase I clinical trial for '
                        'the treatment of acute myeloid leukemia (AML); and '
                        'IMGN632, a CD123-targeting ADC that is in Phase I '
                        'clinical trial for treating AML and blastic '
                        'plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. '
                        'has collaborations with Roche, Amgen/Oxford '
                        'BioTherapeutics, sanofi-aventis U. S. LLC, Biotest '
                        'AG, Bayer HealthCare AG, Novartis Institutes for '
                        'BioMedical Research, Inc., CytomX Therapeutics, Inc., '
                        'Takeda Pharmaceutical Company Limited, Fusion '
                        'Pharmaceuticals Inc., Debiopharm International SA, '
                        'Jazz Pharmaceuticals Ireland Limited, and '
                        'MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 '
                        'and is headquartered in Waltham, Massachusetts.',
 'longName': 'ImmunoGen, Inc.',
 'market': 'us_market',
 'marketCap': 737737408,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_29794',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -89470000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.38,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781-895-0600',
 'previousClose': 4.41,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 8.482275,
 'profitMargins': -1.0287,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.38,
 'regularMarketDayLow': 4.185,
 'regularMarketOpen': 4.38,
 'regularMarketPreviousClose': 4.41,
 'regularMarketPrice': 4.38,
 'regularMarketVolume': 1958444,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 174406000,
 'sharesPercentSharesOut': 0.0945,
 'sharesShort': 16477343,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 12072735,
 'shortName': 'ImmunoGen, Inc.',
 'shortPercentOfFloat': 0.106000006,
 'shortRatio': 7.18,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'IMGN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.584,
 'twoHundredDayAverage': 4.3340287,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '133c6781-87f8-396c-aba6-e5872f74f481',
 'volume': 1958444,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.immunogen.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}